The CDK4/CDK6 inhibitor abemaciclib inhibits transcriptional targets which facilitate growth in ER plus breast cancer cells

被引：1
|
作者：
McNulty, Ann M.
Burke, Teresa
Dempsey, Jack A.
Marchal, Christophe C.
Schade, Andrew E.
Szpurka, Hadrian P.
Dowless, Michele S.
Stephens, Jennifer
Stephens, Jennifer
Edmondson, Denise
Stayrook, Keith
Caldwell, William C.
Buchanan, Sean
Merzoug, Farhana F.
Beckmann, Richard P.
机构：
来源：
MOLECULAR CANCER RESEARCH | 2016年 / 14卷
关键词：
D O I：
10.1158/1557-3125.CELLCYCLE16-A12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A12
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    [J]. FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [2] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [3] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    [J]. MOLECULAR CANCER RESEARCH, 2016, 14
  • [4] Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6
    Gong, Xuegian
    Chio, Li -Chun
    Lallena, MaryJo
    Merzoug, Farhana
    Chu, Shaoyou
    Webster, Yue
    Dempsey, Jack
    Ma, Xiwen
    De Dios, Alfonso
    Beckman, Richard
    Buchanan, Sean G.
    [J]. CANCER RESEARCH, 2015, 75
  • [5] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    [J]. CANCER RESEARCH, 2022, 82 (12)
  • [6] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [7] The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6
    Burke, Teresa
    Torres, Raquel
    McNulty, Ann
    Dempsey, Jack
    Kolis, Stanley
    Kulanthaivel, Palaniappan
    Beckmann, Richard
    [J]. CANCER RESEARCH, 2016, 76
  • [8] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    [J]. Nature Reviews Cancer, 2022, 22 : 356 - 372
  • [9] Targeting CDK4 and CDK6 in cancer
    Goel, Shom
    Bergholz, Johann S.
    Zhao, Jean J.
    [J]. NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
  • [10] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    [J]. CANCER RESEARCH, 2016, 76
12345